116 related articles for article (PubMed ID: 30470301)
1. Regulators of Asymmetric Cell Division in Breast Cancer.
Ragoussis J
Trends Cancer; 2018 Dec; 4(12):798-801. PubMed ID: 30470301
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer.
Granit RZ; Masury H; Condiotti R; Fixler Y; Gabai Y; Glikman T; Dalin S; Winter E; Nevo Y; Carmon E; Sella T; Sonnenblick A; Peretz T; Lehmann U; Paz K; Piccioni F; Regev A; Root DE; Ben-Porath I
Cell Rep; 2018 Sep; 24(12):3237-3250. PubMed ID: 30232005
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNAs (lncRNAs) in triple negative breast cancer.
Wang Q; Gao S; Li H; Lv M; Lu C
J Cell Physiol; 2017 Dec; 232(12):3226-3233. PubMed ID: 28138992
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
5. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
6. Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
Wang S; Liang Y; Chang W; Hu B; Zhang Y
Med Sci Monit; 2018 Apr; 24():1912-1923. PubMed ID: 29605826
[TBL] [Abstract][Full Text] [Related]
7. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
8. The functional role of Notch signaling in triple-negative breast cancer.
Speiser JJ; Erşahin C; Osipo C
Vitam Horm; 2013; 93():277-306. PubMed ID: 23810012
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
10. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors.
Yang F; Cao L; Sun Z; Jin J; Fang H; Zhang W; Guan X
Int J Biol Sci; 2016; 12(12):1568-1577. PubMed ID: 27994520
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
13. The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cells.
Pamarthy S; Jaiswal MK; Kulshreshtha A; Katara GK; Gilman-Sachs A; Beaman KD
Oncotarget; 2015 Oct; 6(33):34206-20. PubMed ID: 26418877
[TBL] [Abstract][Full Text] [Related]
14. Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.
He J; Yang J; Chen W; Wu H; Yuan Z; Wang K; Li G; Sun J; Yu L
PLoS One; 2015; 10(6):e0129842. PubMed ID: 26103053
[TBL] [Abstract][Full Text] [Related]
15. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
[TBL] [Abstract][Full Text] [Related]
16. Targeting CSC in a Most Aggressive Subtype of Breast Cancer TNBC.
Bao B; Prasad AS
Adv Exp Med Biol; 2019; 1152():311-334. PubMed ID: 31456192
[TBL] [Abstract][Full Text] [Related]
17. Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation.
Velloso FJ; Campos AR; Sogayar MC; Correa RG
BMC Genomics; 2019 Feb; 20(1):152. PubMed ID: 30791886
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
Jiang T; Shi W; Wali VB; Pongor LS; Li C; Lau R; Győrffy B; Lifton RP; Symmans WF; Pusztai L; Hatzis C
PLoS Med; 2016 Dec; 13(12):e1002193. PubMed ID: 27959926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
